Safety and Tolerability of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302

Prince, H. M. M., Geskin, L. J., Akilov, O. E., Kuzel, T. M., Querfeld, C., Ooi, C. E., Xing, D., Sauter, N., Singh, P., Czuczman, M., & Foss, F. M. (2022). Safety and Tolerability of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302. Blood, 140(Supplement 1), 6577–6578. https://doi.org/10.1182/blood-2022-167564

Authors:

H. Miles Prince

Larisa J. Geskin

Oleg E. Akilov

Timothy M. Kuzel

Christiane Querfeld

Chean Eng Ooi

Dongyuan Xing

Nicholas Sauter

Rajesh Singh

Myron S. Czuczman

Francine M. Foss